makrani.com
Makrani and Associates
A

PrimeraDx Appoints David Jackson as VP of Business Development

MANSFIELD, Mass., Jan. 3, 2012 /PRNewswire/ -- PrimeraDx today announced that David Jackson has been appointed as the Vice President of Business Development.

"David has extensive capabilities in companion diagnostic partnerships, and his experience with DxS and Qiagen is well aligned with the company's strategy to be the platform of choice in the burgeoning companion diagnostics market," said Matt McManus, President and CEO, PrimeraDx.

"PrimeraDx has the most innovative qPCR based MDx platform in this space," commented Dr. Jackson.  "The strong growth in complex, molecular-based companion diagnostic assays makes this an exciting time to develop strategic alliances based around the high multiplex and multi-modal capabilities of the ICEPlex platform."

David Jackson has over 13 years' experience in the healthcare technology and investment industries.  Most recently David was employed at Qiagen as a member of the Companion Diagnostics Partnerships team in Global Business Development. Prior to Qiagen he held a similar VP role with DxS, which was acquired by Qiagen in 2009.  He has held leadership positions in business and corporate development; strategic marketing; commercialization; and intellectual property analysis. Dr. Jackson earned a doctorate in the medical sciences from the Boston University School of Medicine; is trained and experienced as a US Patent Agent and Securities Analyst.

About PrimeraDx

PrimeraDx is a molecular diagnostics company that has developed, and is commercializing, a novel, game-changing clinical platform which combines PCR with capillary electrophoresis.  The result of combining these two well-known technologies into a bench-top instrument is the ability to deliver highly multiplexed and quantitative, answers to the clinic.  The company is pursuing a two-pronged strategy to sell the system in an Open Platform Mode to clinical labs and to collaborate with pharmaceutical companies to develop high-value companion and enabling diagnostic products.  Users can easily design very complex multi-modal assays that test for disparate target types, like SNPs, expression biomarkers, microRNAs and fusion genes.  PrimeraDx's technology represents the next generation of quantitative PCR.  The Company is backed by a strong group of experienced venture-capital investors, including Abingworth, InterWest Partners, CHL Medical Partners, and Malaysia Technology Development Corporation.  The Company's website is: www.primeradx.com or www.multiplexpcr.com.

CONTACT: Andrew Bond, +1-508-618-2752, [email protected]

SOURCE PrimeraDx



Rate This Article:

Add to Yahoo MyWeb Add to Yahoo Buzz Add to Yahoo Bookmarks Stumble on StumbleUpon Add to Reddit Add to Google Bookmarks Add to Newsvine Add to MySpace Add to Windows Live Add to Furl Add to Fark Add to Facebook Submit to Digg Add to Delicious Add to Blinklist

Comment on "PrimeraDx Appoints David Jackson as VP of Business Development"

Your Name

Your Comments

Verification Code: HFRZJ7
Enter Code:

World, I am


Clothing-Apparel-Garment
AMERICA | Business and Traveling
Textile Commercial Center

Build your own Business and Social Network atINTRO Web Site! Join for Free - Connect and Network with like-minded people and share knowledge, experience, ideas, problems, information and resources!


Review http://makrani.com on alexa.com

Privacy Policy | Copyright/Trademark Notification
web stats